PLK1 and colorectal carcinoma: Mutant KRAS-expressing HCT116 colorectal carcinoma cells have previously been used to investigate resistance to PLK1 inhibition by the ATP-competitive PLK1 inhibitor, BI2536 (Wacker et al., 2012).